<DOC>
	<DOCNO>NCT01227616</DOCNO>
	<brief_summary>The objective study compare efficacy safety repeat dose intravenous ( IV ) ferumoxytol IV iron sucrose treatment IDA subject hemodialysis-dependent CKD .</brief_summary>
	<brief_title>A Phase IV Trial Repeated Doses Ferumoxytol Compared Iron Sucrose Treatment Iron Deficiency Anemia Patients With Chronic Kidney Disease Hemodialysis</brief_title>
	<detailed_description />
	<mesh_term>Anemia</mesh_term>
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Renal Insufficiency , Chronic</mesh_term>
	<mesh_term>Anemia , Iron-Deficiency</mesh_term>
	<mesh_term>Deficiency Diseases</mesh_term>
	<mesh_term>Iron</mesh_term>
	<mesh_term>Ferric oxide , saccharated</mesh_term>
	<mesh_term>Ferrosoferric Oxide</mesh_term>
	<mesh_term>Ferric Compounds</mesh_term>
	<criteria>Key Inclusion Criteria include : 1 . Males females â‰¥18 year age 2 . Diagnosis CKD 3 . Subjects dialysis must dialysis least 3 month prior screen 4 . Female subject childbearing potential sexually active must effective method birth control least 1 month prior screen agree remain birth control completion participation study Key Exclusion Criteria include : 1 . History allergy either oral IV iron 2 . Female subject pregnant intend become pregnant , breastfeeding , within 3 month postpartum , positive serum urine pregnancy test 3 . Parenteral iron therapy within 30 day prior screen red blood cell ( RBC ) /whole blood transfusion within 14 day prior screen plan study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Iron deficiency anemia ( IDA ) , Feraheme , ferumoxytol , chronic kidney disease ( CKD ) , hemodialysis , magnetic resonance imaging ( MRI )</keyword>
</DOC>